1. Emesis due to cancer chemotherapy: results of a prospective, randomised, double-blind trial of varying doses of metoclopramide in the management of cisplatin-induced vomiting;Allan, S.G.; Cornbleet, M.A.; Lockhart, S.P.; Warrington, P.S.; Leonard, R.C.F.; Smyth, J.F.;European journal ofCancer and Clinical Oncology,1984
2. Pharmacological and anti-emetic properties of ondansetron. EuropeanJournal ofCancer and Clinical Oncology 1989; 25(suppl l);Tyers, M.B.; Bunce, K.T.; Humphrey, P.P.A.
3. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting;Marty, M.;European Journal of Cancer and Clinical Oncology,1989
4. Clinical studies with ondansetron in the control of radiationinduced emesis;Priestman, T.J.;European Journal of Cancer and Clinical Oncology,1989
5. Comparison of the 5-hydroxytryptamine5 (serotonin) antagonist ondansetron (GR38032F) with high dose metoclopramide in the control of cisplatininduced emesis;Marty, M.; Pouillart, P.; Scholl, S.; Droz, J.P.; Azab, M.; Brion, N.;N Englj Med,1990